Related Experiment Video

Updated: Jun 21, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Inhibition of bladder tumour growth by histone deacetylase inhibitor

Akira Ozawa1, Nozomu Tanji, Tadahiko Kikugawa

  • 1Department of Urology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.

BJU International
|August 18, 2009
PubMed
Abstract

Insights

Histone deacetylase 1 (HDAC1) is upregulated in bladder cancer. The HDAC inhibitor valproic acid (VPA) showed potential in delaying tumor development in mouse models, suggesting HDAC1 as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Histone deacetylase 1 (HDAC1) is implicated in various cancers.
  • Understanding HDAC1 expression is crucial for developing targeted bladder cancer therapies.

Purpose of the Study:

  • To investigate the expression profile of HDAC1 in bladder cancer.
  • To explore the therapeutic potential of valproic acid (VPA), an HDAC inhibitor, in bladder cancer models.

Main Methods:

  • Analysis of HDAC1 mRNA and protein expression in human bladder cancer tissues and cell lines.
  • In vivo study using a mouse model treated with VPA and N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN).

Main Results:

  • Significantly higher HDAC1 mRNA levels were observed in human bladder cancer specimens.
  • BBN treatment increased HDAC1 mRNA expression in mouse bladders.
  • VPA administration appeared to delay BBN-induced tumor incidence, potentially via p21(WAF1) expression.

Conclusions:

  • HDAC1 is upregulated in bladder cancer and may play a role in its development.
  • HDAC inhibitors like VPA show promise as a therapeutic strategy for bladder cancer.

More Related Videos

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...